Trial Profile
A Phase IIb, Multicenter, Randomized, Double-Blind, Parallel Group, Placebo Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Basmisanil (RO5186582) as Adjunctive Treatment in Patients With Cognitive Impairment Associated With Schizophrenia Treated With Antipsychotics
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Basmisanil (Primary)
- Indications Schizophrenia
- Focus Therapeutic Use
- Sponsors Roche
- 27 Dec 2019 Status changed from active, no longer recruiting to completed.
- 05 Jul 2019 Planned End Date changed from 30 Jan 2020 to 14 Dec 2019.
- 05 Jul 2019 Planned primary completion date changed from 26 Dec 2019 to 14 Dec 2019.